Security
China SXT Pharmaceuticals, Inc. Class A Ordinary Shares · SXTC
SXTCNASDAQCommon stockCurrentCIK 1723980Updated Oct 22, 2026
SXTC price & chart
Loading TradingView…
NASDAQ:SXTC on TradingView ↗About the company
Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, which are a type of Traditional Chinese Medicine that has been processed to be ready for use. For more information, please visit www.sxtchina.com.
In the news
Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) ↗
China SXT Pharmaceuticals, Inc. Announces Share Re-classification ↗
Recent filings
Show 5 more recent filings
Financials
FY 2026 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 26,353,283Source | 30,997,352Source | 14,587,981Source | 22,181,358Source | 22,670,460Source | 24,042,871Source | 23,045,943Source | — | 34,754,574Source | 21,663,508Source | 23,127,057Source | 29,554,056Source |
| Property, Plant and Equipment, NetUSD | 153,079Source | 230,142Source | 809,039Source | 1,012,981Source | 1,296,405Source | 1,462,636Source | 1,759,907Source | — | 117,103Source | 178,561Source | 328,845Source | 962,214Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 8,532Source | 15,898Source | 22,514Source | — | — | — | — | — | 6,328Source | 11,808Source | 19,101Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 21,166,494Source | 18,512,756Source | 11,465,020Source | 2,981,034Source | 31,321Source | 10,353,474Source | 8,247,069Source | 383,606Source | 28,175,865Source | 18,099,019Source | 12,070,345Source | — |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,336,271Source | 1,663,998Source | 1,311,005Source | 3,323,112Source | 3,882,839Source | 5,579,564Source | 4,568,123Source | — | 931,567Source | 1,301,335Source | 1,314,781Source | 1,344,569Source |
| Inventory, NetUSD | 751,346Source | 867,233Source | 493,214Source | 628,186Source | 837,447Source | 867,281Source | 846,281Source | — | 777,059Source | 828,053Source | 794,855Source | 531,254Source |
| Assets, CurrentUSD | 26,042,394Source | 21,988,312Source | 13,495,320Source | 12,359,834Source | 11,661,279Source | 22,059,206Source | 17,542,342Source | — | 34,509,722Source | 21,296,491Source | 14,233,359Source | 19,521,247Source |
| Prepaid Expense and Other Assets, CurrentUSD | 305,137Source | 223,007Source | 137,978Source | 1,040,035Source | 1,816,640Source | 2,174,229Source | 2,022,769Source | — | 372,392Source | 319,058Source | 31,634Source | 230,642Source |
| Operating Lease, Right-of-Use AssetUSD | — | 213,068Source | — | — | — | — | — | — | 121,421Source | 176,648Source | — | 306,050Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 6,119,748Source | 15,962,396Source | 9,511,646Source | 7,291,743Source | 8,878,775Source | 5,521,668Source | 11,636,808Source | — | 5,047,152Source | 6,223,746Source | 9,196,611Source | 14,862,761Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 55,384,646Source | 7,728,820Source | 1,454,756Source | 288,085Source | 67,438Source | 62,057Source | 23,224Source | — | 64,125,702Source | 44,530,601Source | 4,352,290Source | 913,785Source |
| Additional Paid in CapitalUSD | — | — | 35,949,681Source | 32,563,812Source | 26,009,434Source | 24,233,773Source | 11,407,028Source | — | — | — | — | 35,588,214Source |
| Retained Earnings (Accumulated Deficit)USD | -34,384,120Source | -25,514,233Source | -31,309,291Source | -17,182,887Source | -13,044,007Source | -5,822,742Source | 735,803Source | — | -34,220,402Source | -28,015,317Source | -24,711,665Source | -21,613,133Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -766,991Source | -568,853Source | -1,018,811Source | -779,395Source | 758,820Source | 48,115Source | -756,920Source | — | -197,878Source | -1,075,522Source | -1,025,795Source | -197,571Source |
| Stockholders' Equity Attributable to ParentUSD | 20,233,535Source | 15,034,956Source | 5,076,335Source | 14,547,996Source | 13,791,685Source | 18,521,203Source | 11,409,135Source | 4,601,895Source | 29,707,422Source | 15,439,762Source | 13,930,446Source | 14,691,295Source |
| Additional Paid in Capital, Common StockUSD | — | 33,389,222Source | — | — | — | — | — | — | — | — | 35,315,616Source | — |
| Liabilities and EquityUSD | 26,353,283Source | 30,997,352Source | 14,587,981Source | 22,181,358Source | 22,670,460Source | 24,042,871Source | 23,045,943Source | — | 34,754,574Source | 21,663,508Source | 23,127,057Source | 29,554,056Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 5,961,486Source | 15,664,385Source | 9,200,134Source | 7,291,743Source | 8,878,775Source | 5,506,455Source | 10,763,526Source | — | 4,349,320Source | 6,012,063Source | 8,901,944Source | 14,496,938Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 58,089Source |
| Accounts Payable, CurrentUSD | 530,662Source | 1,662,730Source | 1,315,855Source | 1,561,203Source | 1,492,578Source | 1,358,568Source | 1,959,426Source | — | 497,648Source | 1,158,298Source | 1,279,516Source | 1,377,850Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 247,961Source |
| Additional Financial Items | ||||||||||||
| Long-term Debt, Current MaturitiesUSD | 4,475Source | 9,080Source | 19,737Source | — | — | — | — | — | — | 8,781Source | 21,329Source | 7,863Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 73,102Source | 115,344Source | 106,575Source | — | — | — | — | — | 644,390Source | 96,264Source | 117,129Source | 117,862Source |
| Accounts Receivable, after Allowance for Credit Loss | — | — | — | —Source | —Source | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | 73,668Source | 82,297Source | 203,247Source | 250,162Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | — | 5,305,739Source | — | 352,100Source | — |
| Changes in operating assets and liabilities: | |||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | -291,134Source | 257,085Source | 321,422Source | -912,947Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | — | -36,219Source | 14,530Source | 219,646Source | -408,951Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | — | -693,481Source | -114,081Source | -29,254Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | — | -4,017,456Source | -2,345,333Source | -1,928,053Source | -80,757Source |
| Cash flows from investing activities: | |||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | -1,250,921Source | 63,516Source | 26,423Source | -12,303Source |
| Cash flows from financing activities: | |||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | 14,433,521Source | 8,399,153Source | -2,624,428Source | 2,941,602Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | 10,046,801Source | 6,052,245Source | -5,291,291Source | 1,798,859Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 21,197,495Source | 18,512,756Source | 11,465,020Source | 2,981,034Source | 31,321Source | 10,353,474Source | 8,324,227Source | 28,176,233Source | 18,129,432Source | 12,077,187Source | 17,368,478Source |
| Supplemental disclosure of cash flow information: | |||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | 21,451Source | 21,239Source | 24,533Source | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | — | — | 13,047Source |
| Additional Financial Items | |||||||||||
| Accretion ExpenseUSD | — | — | — | — | — | — | — | — | 520,787Source | 292,771Source | — |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | 5,825Source | 7,238Source | 7,459Source | 7,932Source |
| Deferred Other Tax Expense (Benefit)USD | — | — | — | — | — | — | — | -273,385Source | -1,441,907Source | -1,250,105Source | — |
| DepreciationUSD | — | — | — | — | — | — | — | — | 75,059Source | 195,788Source | 242,230Source |
| Depreciation, NonproductionUSD | — | — | — | — | — | — | — | 67,843Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | — | — | 65,539Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | -10,466Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | -335,654Source |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | — | 7,127,450Source | 2,758,047Source | 2,635,622Source | 5,646,328Source |
| InterestExpenseNonoperatingUSD | — | — | — | — | — | — | — | 62,965Source | 648,221Source | 544,279Source | — |
| Inventory Write-downUSD | — | — | — | — | — | — | — | 53,955Source | -22,863Source | -72,057Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | — | — | — | — | — | -6,205,085Source | -3,303,652Source | -3,098,532Source | -5,934,772Source |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | 917,848Source | -623,173Source | -583,315Source | -327,263Source |
| Operating ExpensesUSD | — | — | — | — | — | — | — | 7,371,635Source | 3,047,906Source | 3,069,188Source | 6,033,780Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | 69,551Source | 69,343Source | 69,819Source | 73,034Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | 149,513Source |
| Other Operating Income (Expense), NetUSD | — | — | — | — | — | — | — | 980,813Source | 25,048Source | -39,036Source | — |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | 135,000Source | 110,362Source | 431,737Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | 1,138,052Source | 1,740,907Source | — | — |
income statement · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | 1,928,497Source | 1,971,679Source |
| Cost of Goods and Services Sold | —Source | —Source | —Source | —Source |
| Operating Income (Loss)USD | -7,122,933Source | -2,680,479Source | -2,515,217Source | -5,607,509Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 149,513Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -6,205,085Source | -3,303,652Source | -3,098,532Source | — |
| Net Income (Loss) Attributable to ParentUSD | -6,205,085Source | -3,303,652Source | -3,098,532Source | -5,934,772Source |
| Earnings Per Share, BasicUSD per share | -9.13Source | -2.32Source | -3.57Source | -0.89Source |
| Earnings Per Share, DilutedUSD per share | -9.13Source | -2.32Source | -3.57Source | -0.89Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 679,648Source | 1,423,301Source | 867,422Source | 6,674,327Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 679,648Source | 1,423,301Source | 867,422Source | 6,674,327Source |
| Interest Expense (non-operating)USD | 62,965Source | 648,221Source | 544,279Source | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 5,825Source | 7,238Source | 7,459Source | 7,932Source |
| General and Administrative ExpenseUSD | 7,127,450Source | 2,758,047Source | 2,635,622Source | 5,646,328Source |
| Gross ProfitUSD | 248,702Source | 367,427Source | 553,971Source | 426,271Source |
| Income (Loss) Attributable to Parent, before TaxUSD | — | — | -3,098,532Source | -5,934,772Source |
| Interest ExpenseUSD | — | — | — | 476,776Source |
| Interest Expense, DebtUSD | — | 106,238Source | — | — |
| Labor and Related ExpenseUSD | 236,726Source | 273,580Source | 828,341Source | — |
| Marketing and Advertising ExpenseUSD | 89,488Source | 108,822Source | — | — |
| Nonoperating Income (Expense)USD | 917,848Source | -623,173Source | -583,315Source | -327,263Source |
| Operating ExpensesUSD | 7,371,635Source | 3,047,906Source | 3,069,188Source | 6,033,780Source |
| Operating Lease, ExpenseUSD | 69,551Source | 69,343Source | 69,819Source | 73,034Source |
| Other ExpensesUSD | — | — | — | 3,250,000Source |
| Other General and Administrative ExpenseUSD | 222,560Source | 379,997Source | 299,564Source | — |
| Other Operating Income (Expense), NetUSD | 980,813Source | 25,048Source | -39,036Source | — |
| Research and Development ExpenseUSD | — | — | 184,194Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 1,138,052Source | 1,740,907Source | — | — |
| Selling and Marketing ExpenseUSD | 244,185Source | 289,859Source | 433,566Source | 387,452Source |
| Selling ExpenseUSD | 6,958Source | 25,184Source | 16,176Source | — |
Offerings
Registration 333-297305
Filing attachments
ea030919801ex99-1.htm · 6-K · 2026-10-21
Exhibit 99.1 FOR IMMEDIATE RELEASE China SXT Pharmaceuticals Inc Announces Termination of Additional Purchase Right TAIZHOU, China, Oct. 21, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the “Company”), today announced that it has entered into a termination letter agreement with the purchasers in its registered direct offering announced on October 8, 2026 (the “Offering”). Under the termination letter agreement, the Company and the purchasers have terminated in full the…
Read attachment ↗ea030821701ex4-1.htm · 6-K · 2026-10-09
Exhibit 4.1 PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT CHINA SXT PHARMACEUTICALS, INC. Warrant Shares: [____] Issuance Date: October 9, 2026 ────────────────────────────────────────────────────────────── THIS PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [______________] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth at any time on or after t…
Read attachment ↗ea030821701ex4-2.htm · 6-K · 2026-10-09
Exhibit 4.2 ORDINARY SHARE PURCHASE WARRANT CHINA SXT PHARMACEUTICALS, INC. Warrant Shares: ___________________ Initial Exercise Date: October 9, 2026 Issue Date: October 9, 2026 ─────────────────────────────────────────────────────────────────────────────────── THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the li…
Read attachment ↗ea030809401ex99-1.htm · 6-K · 2026-10-08
Exhibit 99.1 China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering TAIZHOU, China, Oct. 8, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the “Company”), today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 8,000,000 Class A ordinary shares of the company, no par value per share (the “Shares”) (or pre-funded warrants in lieu thereof), at a purchase price o…
Read attachment ↗ea030799301ex4-1.htm · 6-K · 2026-10-08
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A T…
Read attachment ↗ea029910801ex4-1.htm · 6-K · 2026-07-24
Exhibit 4.1 ORDINARY SHARE PURCHASE WARRANT CHINA SXT PHARMACEUTICALS, INC. Warrant Shares: __________ Initial Exercise Date: July 24, 2026 Issue Date: July 24, 2026 ──────────────────────────────────────────────────────────────────────── THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the l…
Read attachment ↗